Sign In
Buy ANAB
$51.24
-0.0200 (-0.0390%)
At Close: Jun 03, 2026
GSK's Jemperli Effective Against First-Line Endometrial Cancer
04:45pm, Tuesday, 28'th Mar 2023
A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates
06:48pm, Wednesday, 01'st Mar 2023
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -1.09% and 16.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
06:56pm, Monday, 21'st Nov 2022 GlobeNewswire Inc.
SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Da
Expert Ratings for AnaptysBio
08:07pm, Wednesday, 09'th Nov 2022 Benzinga
Over the past 3 months, 4 analysts have published their opinion on AnaptysBio (NASDAQ:ANAB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a comp
AnaptysBio to Participate in Upcoming November Investor Conferences
07:10pm, Wednesday, 09'th Nov 2022 GlobeNewswire Inc.
SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Da
AnaptysBio to Participate in Upcoming November Investor Conferences
02:10pm, Wednesday, 09'th Nov 2022
SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Misses Revenue Estimates
10:55pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -151.06% and 92.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Misses Revenue Estimates
10:35pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -9.62% and 97.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Misses Revenue Estimates
07:33pm, Tuesday, 08'th Nov 2022
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -151.06% and 92.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
02:27pm, Tuesday, 01'st Nov 2022 Benzinga
Upgrades
For AnaptysBio Inc (NASDAQ:ANAB), Guggenheim upgraded the previous rating of Neutral to Buy. AnaptysBio earned $1.15 in the second quarter, compared to $0.02 in the year-ago quarter. The sto
AnaptysBio, Inc. (ANAB) Just Flashed Golden Cross Signal: Do You Buy?
01:55pm, Thursday, 13'th Oct 2022 Zacks Investment Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal
03:02pm, Thursday, 06'th Oct 2022 Zacks Investment Research
GSK's (GSK) mid-stage study, evaluating the combination of its cancer drug Jemperli with chemotherapy in non-small cell lung cancer, meets the primary endpoint of objective response rate.
HC Wainwright Sees 40% Upside For This Once Battered Stock With Pipeline Turnaround
06:02pm, Monday, 19'th Sep 2022 Benzinga
HC Wainwright is assuming coverage on AnaptysBio Inc (NASDAQ: ANAB) with a Buy Rating and a price target of $35 at a unique inflection point since it was founded in 2005.
The company's lead ass
This Analyst Slashes PT On Rent the Runway By Around 43%, Plus JP Morgan Predicts $84 For Oracle
03:14pm, Tuesday, 13'th Sep 2022 Benzinga
Credit Suisse cut the price target for Rent the Runway, Inc. (NASDAQ: RENT) from $7 to $4. Rent the Runway shares fell 30.6% to trade at $3.42 on Tuesday.
Truist Securities cut the price target on A
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2022
02:13pm, Tuesday, 13'th Sep 2022 Benzinga
Upgrades
See all analyst ratings upgrades.
Downgrades
Argus Research downgraded the previous rating for Tyson Foods Inc (NYSE:TSN) from Buy to Hold. In the third quarter, Tyson Foods showed an EPS of
